- Home
- LAZR vs ACRS Comparison
LAZR vs ACRS Comparison
Compare LAZR & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAZR
- ACRS
- Stock Information
- Founded
- LAZR 2012
- ACRS 2012
- Country
- LAZR United States
- ACRS United States
- Employees
- LAZR N/A
- ACRS N/A
- Industry
- LAZR Auto Parts:O.E.M.
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- LAZR Consumer Discretionary
- ACRS Health Care
- Exchange
- LAZR Nasdaq
- ACRS Nasdaq
- Market Cap
- LAZR 176.7M
- ACRS 165.7M
- IPO Year
- LAZR N/A
- ACRS 2015
- Fundamental
- Price
- LAZR $2.00
- ACRS $1.80
- Analyst Decision
- LAZR Hold
- ACRS Strong Buy
- Analyst Count
- LAZR 5
- ACRS 9
- Target Price
- LAZR $15.25
- ACRS $9.25
- AVG Volume (30 Days)
- LAZR 4.1M
- ACRS 1.4M
- Earning Date
- LAZR 08-12-2025
- ACRS 08-07-2025
- Dividend Yield
- LAZR N/A
- ACRS N/A
- EPS Growth
- LAZR N/A
- ACRS N/A
- EPS
- LAZR N/A
- ACRS N/A
- Revenue
- LAZR $72,496,000.00
- ACRS $16,789,000.00
- Revenue This Year
- LAZR $16.78
- ACRS N/A
- Revenue Next Year
- LAZR $29.92
- ACRS $8.11
- P/E Ratio
- LAZR N/A
- ACRS N/A
- Revenue Growth
- LAZR N/A
- ACRS N/A
- 52 Week Low
- LAZR $1.89
- ACRS $1.05
- 52 Week High
- LAZR $18.60
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- LAZR 32.42
- ACRS 62.45
- Support Level
- LAZR $1.89
- ACRS $1.75
- Resistance Level
- LAZR $3.02
- ACRS $1.92
- Average True Range (ATR)
- LAZR 0.16
- ACRS 0.09
- MACD
- LAZR -0.07
- ACRS 0.01
- Stochastic Oscillator
- LAZR 9.73
- ACRS 70.00
About LAZR Luminar Technologies Inc.
Luminar Technologies Inc is an automotive technology company ushering in a new era of vehicle safety and autonomy. It operates its business through the following segments: Autonomy Solutions and Advanced Technologies and Services. The majority of its revenue is generated from the Autonomy Solutions segment, which engages in the design, manufacturing, and sale of LiDAR sensors, catering mainly to the OEMs in the automobile, commercial vehicle, robo-taxi, and adjacent industries. The Advanced Technologies and Services segment provides semiconductors and related components, as well as design, test, and consulting services to the Autonomy Solutions segment and various third-party customers. Geographically, the company derives its key revenue from North America.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.